Equities

Integra Lifesciences Holdings Corp

Integra Lifesciences Holdings Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)17.47
  • Today's Change-0.06 / -0.34%
  • Shares traded798.09k
  • 1 Year change-55.51%
  • Beta1.0973
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The Company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.

  • Revenue in USD (TTM)1.57bn
  • Net income in USD23.65m
  • Incorporated1989
  • Employees3.95k
  • Location
    Integra Lifesciences Holdings Corp1100 Campus RoadPRINCETON 08540United StatesUSA
  • Phone+1 (609) 275-0500
  • Fax+1 (609) 750-4277
  • Websitehttps://www.integralife.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
IART:NSQ since
announced
Transaction
value
Acclarent IncDeal completed13 Dec 202313 Dec 2023Deal completed-57.31%280.00m
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Embecta Corp1.12bn69.70m906.50m2.20k13.02--8.370.81021.211.2119.36-13.240.88822.1111.60508,590.905.53--7.91--66.42--6.23--1.612.061.88---0.7703---68.52------
Bioventus Inc536.89m-41.96m938.48m1.03k--6.22--1.75-0.6595-0.65958.481.860.65911.954.18553,495.90-6.70-5.52-9.65-7.2766.5368.25-10.16-10.940.9561.080.6697--0.04459.936.91--23.51--
Figs Inc550.80m18.68m961.94m354.0054.722.3943.121.750.10290.10293.042.351.181.2358.021,555,932.003.99--4.65--68.02--3.39--3.89--0.00--7.87--6.85------
Artivion Inc376.97m-8.32m1.05bn1.50k--3.5670.162.79-0.2076-0.20769.117.060.4811.675.44251,316.00-1.07-2.20-1.15-2.3664.6365.51-2.22-5.344.041.070.5177--12.826.14-60.09--5.13--
Avanos Medical Inc682.40m7.00m1.13bn3.77k161.120.927721.731.660.15320.167114.7126.620.41051.935.20180,960.000.4211-0.65270.4737-0.733855.8254.451.03-1.601.497.060.1253---1.580.6357-146.05---18.37--
Pulse Biosciences Inc0.00-44.02m1.15bn56.00--38.36-----0.7916-0.79160.000.48830.00----0.00-76.43-93.21-84.97-104.99-------12,332.25----0.00---100.00--27.85---15.20--
BioLife Solutions Inc121.17m-53.87m1.19bn409.00--3.69--9.79-1.21-1.642.696.970.29991.995.39296,254.30-13.33-13.76-14.60-15.0441.2736.76-44.46-42.991.81-5.980.0651---11.4348.6552.49--86.35--
Establishment Labs Holdings Inc151.35m-83.20m1.23bn857.00--27.28--8.12-3.11-3.115.621.610.53070.85252.72166,685.00-29.17-33.22-34.29-41.1266.0464.73-54.97-43.192.91-20.680.8114--2.1321.96-4.38--69.16--
Owens & Minor, Inc.10.53bn-42.44m1.24bn13.70k--1.445.150.1174-0.5532-0.5532137.9811.171.996.9515.78768,728.30-0.80141.32-1.252.0720.7816.48-0.4030.56140.51412.110.70760.7983.801.87-284.47--25.91--
Inmode Ltd416.63m149.20m1.35bn581.0010.241.959.033.251.731.734.849.090.52281.6211.78717,084.3018.7231.3220.7935.6482.2784.4635.8139.658.09--0.000.008.3237.4922.5454.6513.10--
Integra Lifesciences Holdings Corp1.57bn23.65m1.36bn3.95k59.000.88348.890.86520.29610.296120.0219.770.3991.555.81396,986.100.60233.330.66183.6861.5463.671.517.992.105.880.54330.00-1.030.9219-62.482.19-2.97--
AtriCure Inc429.95m-40.12m1.40bn1.20k--3.04--3.26-0.8606-0.86069.229.490.72171.688.27358,294.20-6.73-3.72-7.58-4.1074.8474.36-9.33-7.642.93-11.790.12--20.8414.6434.49--46.56--
Adapthealth Corp3.26bn-692.75m1.52bn10.70k--1.01--0.466-5.17-5.1724.2911.140.671422.228.12304,741.80-14.15-4.34-15.89-4.8918.6318.28-21.07-6.470.94382.170.5866--7.73---1,169.99------
STAAR Surgical Co332.94m16.61m1.55bn1.06k94.333.8070.384.670.3350.3356.758.320.69842.133.54315,286.003.496.773.997.9079.2476.894.999.165.21--0.00030.0013.3721.07-46.1833.8551.95--
Warby Parker Inc719.93m-45.90m1.77bn2.14k--5.36--2.45-0.387-0.3876.052.751.225.68603.46336,415.40-7.78---9.68--55.3757.49-6.38-14.532.11--0.00--11.9819.6742.75------
Data as of Sep 19 2024. Currency figures normalised to Integra Lifesciences Holdings Corp's reporting currency: US Dollar USD

Institutional shareholders

51.52%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 202410.22m13.17%
The Vanguard Group, Inc.as of 31 Jul 20247.80m10.06%
Wellington Management Co. LLPas of 30 Jun 20243.73m4.80%
Cooke & Bieler LPas of 30 Jun 20243.51m4.53%
AllianceBernstein LPas of 30 Jun 20243.09m3.98%
SSgA Funds Management, Inc.as of 30 Jun 20242.78m3.58%
Boston Management & Researchas of 30 Jun 20242.74m3.53%
Capital Research & Management Co. (Global Investors)as of 30 Jun 20242.43m3.13%
Fuller & Thaler Asset Management, Inc.as of 30 Jun 20241.84m2.37%
Geode Capital Management LLCas of 30 Jun 20241.83m2.36%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.